Pregled bibliografske jedinice broj: 1218645
Cellular model of Parkinson’s disease for safety testing of gold-based nanodelivery system
Cellular model of Parkinson’s disease for safety testing of gold-based nanodelivery system // Arhiv za higijenu rada i toksikologiju
Zagreb, Hrvatska, 2022. str. 14-14 (predavanje, domaća recenzija, sažetak, znanstveni)
CROSBI ID: 1218645 Za ispravke kontaktirajte CROSBI podršku putem web obrasca
Naslov
Cellular model of Parkinson’s disease for safety
testing of gold-based nanodelivery system
Autori
Mamić, Ivan ; Beus, Maja ; Peranić, Nikolina ; Kalčec, Nikolina ; Turčić, Petra ; Vinković Vrček, Ivana
Vrsta, podvrsta i kategorija rada
Sažeci sa skupova, sažetak, znanstveni
Izvornik
Arhiv za higijenu rada i toksikologiju
/ - , 2022, 14-14
Skup
Synergy at chemistry-nanotechnology interface
Mjesto i datum
Zagreb, Hrvatska, 28.05.2022
Vrsta sudjelovanja
Predavanje
Vrsta recenzije
Domaća recenzija
Ključne riječi
Parkinson`s disease, gold nanoparticles
Sažetak
Parkinson`s disease is the second most common neurodegenerative disorder (1). It is characterized by early prominent death of dopaminergic neurons in substantia nigra which results in classical motor symptoms of the disease: rigidity, rest tremor, bradykinesia, and postural instability (2). Although initially described more than 200 years ago (3), not a single drug is able to alter the natural history of the disease. Mainstay therapy is levodopa - a precursor in the synthesis of the dopamine - that can cross the blood brain barrier. Since introduction to the therapy, 50 years ago, many improvements have been made to enhance its efficiency and reduce side effects. However, passage of the blood brain barrier is still relatively poor, side effects can pose significant burden and long- term therapy is associated with motor complications. Motor complications are, at least in part, due to the fluctuations of levodopa concentrations in the plasma. In many cases these complications can be so intense that the only options is to discontinue the drug which inevitably leads to rapid decline in the quality of the life. Therefore, new formulations of levodopa, that can increase delivery of the drug to the brain and reduce plasma fluctuations are needed. This study tested the safety of phosphoglucomutase (PGM) functionalized gold nanoparticles (AuNP) as levodopa carrier using differentiated neuroblastoma (SH-SY5Y) cells as in vitro model of Parkinson`s disease. AuNPs shape, size, and surface charge were determined with transmission electron microscopy (TEM), dynamic light scattering (DLS), and zeta potential measurements, respectively. Cell viability and apoptosis induction test were performed using flow cytometry, while oxidative stress was determined by measuring the concentration of reactive oxygen species, glutathione (GSH) and mitochondrial membrane potential. In all experiments levodopa loaded AuNPs were compared with AuNPs and levodopa alone.
Izvorni jezik
Engleski
POVEZANOST RADA
Projekti:
HRZZ-PZS-2019-02-4323 - Siguran pristup za razvoj nano-sustava za ciljanu isporuku lijekova u mozak (SENDER) (Vinković Vrček, Ivana, HRZZ ) ( CroRIS)
Profili:
Nikolina Kalčec
(autor)
Ivan Mamić
(autor)
Ivana Vinković Vrček
(autor)
Petra Turčić
(autor)
Nikolina Peranić
(autor)
Maja Beus
(autor)